SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : MRE (medco research)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: DENNIS TULLY who wrote (151)1/4/1999 9:27:00 AM
From: Harold V  Read Replies (1) of 192
 
Dennis, owing MRE for years has indeed be a long haul--$28 as a secondary offering years ago, down to the $8 range, then a long crawl to $16 or so, and finally a stellar year in '98. My main concern now is the analyst estimate that MRE will earn less this year than last--due, I'm assuming, to a greater tax bite. But Sam's right, when MRE gets one of its new adenosine applications approved, the stock will skyrocket. That, tho', raises my second concern: that hopefully MRE now has a team that will be able to get drugs approved by the FDA. It's track record over the last couple of years in this regard is lamentable, in part because they submitted some non-adenoscine drug combinations that offered little if any therapeutic promise. Let's keep the chatter going. Harold V

PS. How do we get Sillicon Investor to revise its reporting of MRE's stock action? SI is truly STUCK on MRE at $20 and change.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News